Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer

BACKGROUND: Dual blockade of both EGFR and VEGFR pathways in EGFR‐mutant NSCLC have shown enhanced antitumor efficacy versus EGFR‐TKIs alone. Apatinib is an orally effective VEGFR‐2 tyrosine kinase inhibitor (TKI). This pilot study aims to evaluate the tolerability, pharmacokinetic profile, and anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhonghan, Zhang, Yang, Luo, Fan, Ma, Yuxiang, Fang, Wenfeng, Zhan, Jing, Li, Su, Yang, Yunpeng, Zhao, Yuanyuan, Hong, Shaodong, Zhou, Ting, Zhang, Yaxiong, Zhao, Shen, Huang, Yan, Zhao, Hongyun, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403827/
https://www.ncbi.nlm.nih.gov/pubmed/32508029
http://dx.doi.org/10.1002/ctm2.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403827/
https://www.ncbi.nlm.nih.gov/pubmed/32508029
http://dx.doi.org/10.1002/ctm2.33

Ejemplares similares